Synonym
G-28315; G28315; G 28315; Sulfinpyrazone; Anturane; Anturanil
IUPAC/Chemical Name
1,2-diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
InChi Key
MBGGBVCUIVRRBF-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
SMILES Code
O=C(C1CCS(C2=CC=CC=C2)=O)N(C3=CC=CC=C3)N(C4=CC=CC=C4)C1=O
Appearance
White to off-white solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
404.48
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2015 Jul 16;7:CD002786. doi: 10.1002/14651858.CD002786.pub3. Review. PubMed PMID: 26184395.
2: Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, Bombardier C. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl. 2014 Sep;92:33-41. doi: 10.3899/jrheum.140460. Review. PubMed PMID: 25180126.
3: Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17. Review. PubMed PMID: 21849262.
4: Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD002786. doi: 10.1002/14651858.CD002786.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD002786. PubMed PMID: 18843633.
5: Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004 Mar;20(3):369-79. Review. PubMed PMID: 15025846.
6: van Gijn J, Algra A. Aspirin and stroke prevention. Thromb Res. 2003 Jun 15;110(5-6):349-53. Review. PubMed PMID: 14592561.
7: Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep. 2001 Feb;3(1):29-35. Review. PubMed PMID: 11177768.
8: Aronow WS. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. Drugs Aging. 1999 Aug;15(2):91-101. Review. PubMed PMID: 10495069.
9: Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999 Apr 1;59(7):1799-806, 1810. Review. PubMed PMID: 10208700.
10: Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998 Jun;45(6):525-38. Review. PubMed PMID: 9663807; PubMed Central PMCID: PMC1873650.
11: Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996 Jun;30(6):416-44. Review. PubMed PMID: 8792056.
12: Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995 Jan 26;332(4):238-48. Review. PubMed PMID: 7808491.
13: Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994 Nov 1;121(9):676-83. Review. PubMed PMID: 7944078.
14: Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf. 1994 Oct;11(4):252-8. Review. PubMed PMID: 7848545.
15: Verry M, Panak E, Cazenave JP. Antiplatelet therapy in the prevention of ischaemic stroke. Nouv Rev Fr Hematol. 1994 Jun;36(3):213-28. Review. PubMed PMID: 7971242.
16: Keyser A. Platelet aggregation inhibitors in neurology. Pharm World Sci. 1993 Dec 17;15(6):243-51. Review. PubMed PMID: 8298583.
17: Jafri SM, Zarowitz B, Goldstein S, Lesch M. The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction. Prog Cardiovasc Dis. 1993 Jul-Aug;36(1):75-83. Review. PubMed PMID: 8321905.
18: Stein PD, Dalen JE, Goldman S, Schwartz L, Turpie AG, Théroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty. Chest. 1992 Oct;102(4 Suppl):508S-515S. Review. PubMed PMID: 1395831.
19: Ferlito S. [Platelet antiaggregants in the treatment of arterial thrombosis]. Minerva Cardioangiol. 1991 Oct;39(10):375-89. Review. Italian. PubMed PMID: 1803283.
20: Wolfe F. Gout and hyperuricemia. Am Fam Physician. 1991 Jun;43(6):2141-50. Review. PubMed PMID: 2042555.
